Abstract
Background: Systemic pulmonary delivery is considered to have advantages over oral or intravenous administration for certain drugs.
Methods: In this article, we review the effects of intrinsic drug properties and drug loading carriers on the pharmacokinetic parameters of inhaled drugs in the context of use in systemic pulmonary delivery.
Results: The delivery of drugs via inhalation can be advisable to achieve a fast onset of action; enhance the systemic bioavailability of drugs with poor oral absorption, including peptides and proteins; avoid invasive administration and improve patient compliance. To optimize the functioning of this delivery system, there is high demand for a systematic understanding of the pharmacokinetic characteristics, which are closely related to the pharmacodynamic and toxicological effects.
Conclusion: The pharmacokinetic parameters of inhaled drug products are affected by many factors, including physiological and pathological variables and the intrinsic drug and formulation properties.
Keywords: Pharmacokinetic, inhaled, systemic delivery, inhaled carriers, drug’s intrinsic property, bioavailability.
Current Pharmaceutical Design
Title:Pharmacokinetic Considerations of Inhaled Pharmaceuticals for Systemic Delivery
Volume: 22 Issue: 17
Author(s): Xiao Hu, Fei-Fei Yang and Yong-Hong Liao
Affiliation:
Keywords: Pharmacokinetic, inhaled, systemic delivery, inhaled carriers, drug’s intrinsic property, bioavailability.
Abstract: Background: Systemic pulmonary delivery is considered to have advantages over oral or intravenous administration for certain drugs.
Methods: In this article, we review the effects of intrinsic drug properties and drug loading carriers on the pharmacokinetic parameters of inhaled drugs in the context of use in systemic pulmonary delivery.
Results: The delivery of drugs via inhalation can be advisable to achieve a fast onset of action; enhance the systemic bioavailability of drugs with poor oral absorption, including peptides and proteins; avoid invasive administration and improve patient compliance. To optimize the functioning of this delivery system, there is high demand for a systematic understanding of the pharmacokinetic characteristics, which are closely related to the pharmacodynamic and toxicological effects.
Conclusion: The pharmacokinetic parameters of inhaled drug products are affected by many factors, including physiological and pathological variables and the intrinsic drug and formulation properties.
Export Options
About this article
Cite this article as:
Hu Xiao, Yang Fei-Fei and Liao Yong-Hong, Pharmacokinetic Considerations of Inhaled Pharmaceuticals for Systemic Delivery, Current Pharmaceutical Design 2016; 22 (17) . https://dx.doi.org/10.2174/1381612822666160128150005
DOI https://dx.doi.org/10.2174/1381612822666160128150005 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacogenomics: Integration into Drug Discovery and Development
Current Topics in Medicinal Chemistry The Podocyte: a Potential Therapeutic Target in Diabetic Nephropathy?
Current Pharmaceutical Design Cardiac Toxicities of Antiangiogenic Therapies
Current Angiogenesis (Discontinued) Should Cushing's Syndrome be Considered as a Disease with High Cardiovascular Risk in Relevant Guidelines?
Current Vascular Pharmacology Lock Stock and Barrel of Wound Healing
Current Pharmaceutical Design Action and Disposition of the β3-Agonist Nebivolol in the Presence of Inflammation; An Alternative to Conventional β1-Blockers
Current Pharmaceutical Design Diabetes Mellitus in Saudi Arabia: A Review of the Recent Literature
Current Diabetes Reviews Blood-Brain Barrier Changes in High Altitude
CNS & Neurological Disorders - Drug Targets Depressed Glucose Consumption at Reperfusion following Brain Ischemia does not Correlate with Mitochondrial Dysfunction and Development of Infarction: An in vivo Positron Emission Tomography Study
Current Neurovascular Research Patent Selections
Recent Patents on Biotechnology Steroid Biosynthesis Inhibitors in the Therapy of Hypercortisolism: Theory and Practice
Current Medicinal Chemistry Role of Kynurenines in the Central and Peripherial Nervous Systems
Current Neurovascular Research Phylogenetic Aspects of Nucleobindin-2/Nesfatin-1
Current Pharmaceutical Design Diminished Renal Function and the Incidence of Heart Failure
Current Cardiology Reviews Older Adults with Amnestic Mild Cognitive Impairment Exhibit Exacerbated Gait Slowing under Dual-Task Challenges
Current Alzheimer Research Correlation between Serum 25 hydroxy vitamin D level and plasminogen activator inhibitor 1 in type 2 diabetic patients
Endocrine, Metabolic & Immune Disorders - Drug Targets Treating Arterial Stiffness in Young and Elderly Patients with the Metabolic Syndrome
Current Pharmaceutical Design Genetic Variability of Matrix Metalloproteinase Genes in Cardiovascular Disease
Current Topics in Medicinal Chemistry Pathogenesis of the Podocytopathy and Proteinuria in Diabetic Glomerulopathy
Current Diabetes Reviews Targeting the Liver in the Metabolic Syndrome: Evidence from Animal Models
Current Pharmaceutical Design